News FDA Approves Reintroduced Cortrophin Gel for MS Exacerbations FDA Approves Reintroduced Cortrophin Gel for MS Exacerbations by Yedida Y Bogachkov PhD | November 2, 2021 Share this article: Share article via email Copy article link The injectable ACTH gel medication Cortrophin Gel (repository corticotropin injection), first introduced in the U.S. in the 1950s, will now be relaunched as a treatment for acute flare-ups in multiple sclerosis (MS) and other autoimmune conditions, following its approval by the U.S. Food and Drug Administration (FDA). In addition to MS, the FDA has now approved Cortrophin Gel for indications that include acute exacerbations from rheumatoid arthritis, and excess protein in the urine due to nephrotic syndrome. ANI Pharmaceuticals is planning a full-scale commercial launch of Cortrophin Gel in early first-quarter 2022, the company announced in a press release. The therapy, which can be injected under the skin (subcutaneously) or into the muscle (intramuscular), had been previously approved by the FDA in 1954 for multiple autoimmune diseases, but it fell out of use in the 1980s. ANI has spent the last five years working to bring the gel back to the market, the company said. āFDAās approval of Cortrophin Gel enables us to bring a much-needed treatment choice to patients with acute exacerbations of multiple sclerosis,ā said Nikhil Lalwani, president and CEO of ANI Pharmaceuticals. Recommended Reading March 2, 2020 News by Patricia Inacio, PhD #ACTRIMS2020 – Acthar Gel Ably Treats MS Relapses, Topline Data Show Cortrophin Gel consists of an adrenocorticotropic hormone (ACTH). It works by enhancing the production of corticosteroids by certain glands in the body, which help to reduce inflammation and more rapidly resolve MS relapses. In recent years, the only repository corticotropin injection available in the U.S. was Mallinckrodt Pharmaceuticals’ Acthar Gel. ANI had previously announced plans to sell its Cortrophin Gel āat a substantial discount,ā potentially enabling more patients to access this treatment. āFor over 30 years, there has only been one available treatment in the ACTH category. With the FDA approval of Cortrophin Gel, patients will now have a significant new treatment option,ā said Mary Pao Seideman, MD, PhD, chief medical officer of ANI Pharmaceuticals. Recommended Reading September 18, 2019 News by Patricia Inacio, PhD #ECTRIMS2019 – Acthar Gel Seen as Cost-effective Late-line Treatment Option for MS Relapses ANI had first acquired the new drug application from Merck (known as MSD outside North America) in 2016. Since then, the company had invested a significant amount of time and resources in establishing and updating its manufacturing procedures and creating a sustainable U.S.-based supply chain. The newly approved product is expected to be available in the U.S. market early next year. āWe are pleased to offer Cortrophin Gel, an established treatment, to provide another option to patients and prescribers,” said Lalwani. “This approval reflects ANIās commitment to the patients and physicians we serve, combined with U.S.-based development and manufacturing.” As part of its commitment to ensuring access to Cortrophin Gel, ANI is creating a patient support program that will include financial assistance for eligible patients. Additional information about this program will become available once the therapy becomes commercially available. Print This Page About the Author Yedida Y Bogachkov PhD Yedida Y. Bogachkov is a science writer for BioNews. She holds a PhD in cellular and molecular pharmacology from the University of Illinois at Chicago. Prior to joining BioNews, she was conducting scientific research analyzing cancer genomics. Sheās a Chicago native and hasnāt moved out of her hometown. Yes, she actually likes snow and enjoys having all four seasons. Yedida likes being out in nature, and in her free time, she can be found outside enjoying the fresh air or baking (inside). She is, unsuccessfully, trying to persuade the rest of her family to enjoy hiking. Yedida is excited to bring her passion for science and her desire to help people to BioNews. Tags ACTH, Acthar Gel, Cortrophin Gel, flare-ups, Mallinckrodt Pharmaceuticals
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study
April 24, 2024 News by Andrea Lobo, PhD Foralumab found to ease fatigue in SPMS patients in access program